cover
Article Per Year (5 Year)
All
Home Page
OAI Link
Editorial Team
Contact
Reviewer
Google Scholar
Contact Name
Anak Agung Gde Putra Wiraguna
Contact Email
editor.balidv@gmail.com
Phone
+6282339990824
Journal Mail Official
editor.balidv@gmail.com
Editorial Address
Dermatology and Venereology Department, Medical Faculty, Universitas Udayana/Prof. dr. I G. N. G. Ngoerah General Hospital, 3rd Floor (Jl. Diponegoro, Dauh Puri Klod, Kecamatan Denpasar Barat, Kota Denpasar, Bali 80113)
Location
Kota denpasar,
Bali
INDONESIA
Bali Dermatology Venereology and Aesthetic Journal
Published by Universitas Udayana
ISSN : 30467985     EISSN : 30467993     DOI : https://doi.org/10.51559/balidervenaesthj.v6i1.33
Core Subject : Health, Science,
Biochemistry, Genetics & Molecular Biology Health Professions Immunology & microbiology Medicine & Pharmacology Public Health
Bali Dermatology Venereology and Aesthetic Journal is an open access; peer-reviewed journal aiming to communicate high-quality research articles, reviews, and general articles in the Dermatology, Venereology and Aesthetic field. The Journal aims to bridge and integrate the intellectual, methodological, and substantive diversity of Dermatology, Venereology and Aesthetic and to encourage a vigorous dialogue between researcher, medical scholars and practitioners. The scope of this journal includes: General dermatology Venereology Cosmetic dermatology/aesthetic Pediatric dermatology Allergy and immunology Skin and tumor surgery Tropical dermatology Genodermatosis (hereditary skin disease) Travel dermatology Traditional, Complementary, and Integrative medicine in dermatology Diagnostic method and artificial intelligence in dermatology
Arjuna Subject : Kedokteran - Dematologi
Articles 5 Documents
 1 
Search results for , issue "BDVJ - Vol. 3 No. 2 (December 2020)" : 5 Documents clear
The effectiveness of galactomyces ferment filtrate, dexpanthenol, and Centella asiatica combination serum in the treatment of post-acne hyperpigmentation We Sagara Dewi; Ivan Kurniadi; Anis Irawan Anwar
Bali Dermatology Venereology and Aesthetic Journal BDVJ - Vol. 3 No. 2 (December 2020)
Publisher : Explorer Front

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.51559/dtmmz489

Abstract

Background: Acne vulgaris is a chronic inflammation of the pilosebaceous gland that may result in non-inflammatory and inflammatory lesions. A hypermelanotic reaction to skin inflammation causes post-acne hyperpigmentation (PAH). It can occur secondary to the inflammation process and, depending on the severity, may persist for a prolonged period. Objective To determine the effectiveness of galactomyces ferment filtrate (GFF), dexpanthenol, and Centella asiatica combination serum in the treatment of PAH Methods: This was a placebo-controlled randomized clinical trial. Sixty-eight subjects were divided into two groups: the experimental group received combination serum while the control group received a placebo for eight weeks. Three drops of serum were applied to the area with PAH twice daily in the morning and night. The melanin, erythema, roughness, and L*, a*, and b* scores were assessed objectively using mexameter, chromameter and skin analyzer every two weeks. Pearson’s correlation test and independent T-test were used to assess the trend of the parameters and compare the results of both groups. Results: The results of statistical calculations using the Pearson correlation test showed the treatment group showed a significant decreasing trend of the melanin and spots score. Both groups showed a significant decreasing trend in erythema, L* score and roughness. However, no significant difference was found between both groups in all parameters. Conclusion: The combination serum may decrease the melanin and spot scores suggesting that it affects the melanocyte activity. It has shown good efficacy in treating PAH.
Dermatology in COVID-19 Pandemic: A review of manifestation, prevention, and treatment of personal protective equipment adverse skin reactions I Gusti Ayu Nitya Indira; I Made Sutha Saskara
Bali Dermatology Venereology and Aesthetic Journal BDVJ - Vol. 3 No. 2 (December 2020)
Publisher : Explorer Front

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.51559/q0sk8q96

Abstract

COVID-19 poses a new challenge to healthcare workers with a new standard of care and managing COVID-19 patients. Healthcare workers must adhere to stricter hand hygiene, and the new personal protective equipment (PPE) protocol brings forth new problems for healthcare workers. Skin problems have become the most common and preventable adverse effects of the daily and prolonged use of PPE. This could inadvertently cause protocol breaches, such as mask touching, scratching, or off-protocol PPE adjustment. Damage in the skin could also cause discomfort, and skin exposure may serve as a new port of entry for a secondary infection. This study reviewed adverse effects, prevention, and therapy of skin problems related to COVID-19 PPE use.
Systematic review of melasma treatments: advantages and disadvantages Sang Ayu Arta Suryantari; Ni Putu Tamara Bidari Sweta; Elvina Veronica; I Gusti Ngurah Bagus Rai Mulya Hartawan; Ni Luh Putu Ratih Vibriyanti Karna
Bali Dermatology Venereology and Aesthetic Journal BDVJ - Vol. 3 No. 2 (December 2020)
Publisher : Explorer Front

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.51559/dy28rh70

Abstract

Background: Melasma is acquired chronic hyperpigmentation mainly affecting women. The pathogenesis of melasma is uncertain, but it is predominantly related to ultraviolet (UV) exposure. Due to its chronic and relapsing nature, melasma is challenging to treat. The currently available treatment often has undesirable side effects and suboptimal results. The treatment principle includes protecting from UV radiation, inhibiting melanin synthesis, and increasing the pathway to remove melanin. Objectives: To define available treatments for melasma and determine advantages and disadvantages, including topical, oral and procedural. Method: Medline, Cochrane library and PubMed databases were searched for articles from January 2011 to June 2020. Only RCTs, comparative, prospective, retrospective and systematic reviews focusing on melasma treatments were extracted, analyzed and discussed. Results: We found 197 studies that met the inclusion and exclusion criteria, with 2314 participants included in this review. The treatments included topical, oral and procedural. In several studies, hydroquinone alone or combination remains the most effective treatment for melasma. Oral and topical tranexamic acid is a beneficial adjuvant treatment in refractory melasma with minimal adverse effects. Procedural treatments such as chemical peels, laser and light-based therapies, and microneedling have mixed and unpredictable results. Overall, the side effects tend to be mild and affect a few of the subjects. Conclusions: The current state of the evidence suggests that some treatments with multiple modalities have their respective advantages and disadvantages. The choice of treatment modality must be adjusted according to the type of melasma, such as its severity, extent and location. A better understanding of melasma through further research may improve the therapy options with the least adverse effects.
Incidence and characteristic of psoriasis patients at Sanjiwani Gianyar Regional Hospital 2018-2019 Annisa Alviariza; Sayu Widyawati
Bali Dermatology Venereology and Aesthetic Journal BDVJ - Vol. 3 No. 2 (December 2020)
Publisher : Explorer Front

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.51559/e49bmc59

Abstract

Introduction: Psoriasis is a chronic inflammatory skin disease characterized by firmly demarcated red plaque covered by a thick squama due to impaired proliferation and differentiation of the epidermis. Diagnosis of psoriasis is based on history taking and clinical features. Treatment is determined based on the patient's clinical characteristics and the severity of the disease. This retrospective study aims to determine the incidence, characteristics, and treatment options of psoriasis patients in the Dermatology and Venereology Polyclinic of Sanjiwani Gianyar Regional Hospital in 2018-2019. Methods: A retrospective study of psoriasis patients at Sanjiwani Gianyar Regional Hospital in 2018-2019. Data collected from medical records includes sociodemographic data, clinical data, and patient treatment history. Results: Within two years, there were 53 cases of psoriasis. The dominance of psoriasis cases was found in men with a ratio of women and men 1:2.31. Of total 53 patients, 37 were male (69.81%)and 16 female patients (30.19%). The most common type was psoriasis vulgaris (73.58%). The most age group was 31-45 years. The most commonly given regimen of therapy was topical corticosteroids plus oral antihistamines (45.28%). The most widely given systemic therapy was methotrexate. Accompanying skin infections were found in 6 cases of psoriasis (11.32%). Conclusion: Based on the results of the study, there were 53 new cases of psoriasis in 2018-2019, psoriasis vulgaris was the most common, the most age group was 31-45 years old, topical corticosteroids with antihistamines were still the main treatment options for psoriasis patients in Sanjiwani Gianyar Regional Hospital.
Focus on the dabrafenib, vemurafenib, and trametinib in the clinical outcome of melanoma: A systematic review and meta-analysis Ida Ayu Widya Anjani; Anak Agung Bagus Putra Indrakusuma; I Gede Krisna Arim Sadeva; Putri Ayu Wulandari; Luh Made Mas Rusyanti; Prima Sanjiwani Saraswati Sudarsa; I Gede Putu Supadmanaba; Desak Made Wihandani
Bali Dermatology Venereology and Aesthetic Journal BDVJ - Vol. 3 No. 2 (December 2020)
Publisher : Explorer Front

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.51559/myphje28

Abstract

Background: Melanoma is the most severe lethal skin cancer, affecting melanin producer cells (melanocytes). Surgery is the most common treatment, whereas, for the advanced stage, the development of treatment is recommended. BRAF (Dabrafenib and Vemurafenib) inhibitor or MEK inhibitor (Trametinib) is the most frequently targeted melanoma therapy due to more than 80% of patients with positive BRAF mutation. In this review, those treatments will be investigated systematically to identify their clinical outcome. Method: This systematic literature review (SLR) was performed from Cochrane, Science Direct, Google Scholar, and Pubmed. Cochrane Risk-of-Bias Tool RoB2 is used to assess RCT studies and New-castle Ottawa Scale Assessment to assess cohort studies by three different assessors. Data analysis was carried out by using Review Manager (RevMan 5.4). Heterogenicity test was assessed by I2 and Chi2 statistic Result: There are 20 studies used in this article (13 RCT and seven cohorts). The overall survival (OS) and progression-free survival (PFS) of the survey that using targeted therapy (vemurafenib, trametinib, or dabrafenib) compare other treatments (chemotherapy, immunotherapy, etc.) showed risk ratio (RR) was 1.12 (95%CI 1.07,1.17; I2=100%; p<0,00001). The OS and PFS with monotherapy compare of vemurafenib, trametinib, or dabrafenib with combination therapy showed RR was 1.09 (95%CI.06,1.13; I2=99%; p<0,00001). Conclusion: BRAF and MEK targeted therapy has a good prognosis for a patient with a positive BRAF gene mutation and could be combined with other treatments for better clinical outcomes rather than monotherapy.

Page 1 of 1 | Total Record : 5

 1 

Filter by Year

2020 2020


Reset
Filter By Issues
All Issue BDVAJ - Volume 8, Issue 1 (2025) BDVAJ - Volume 7, Issue 2 (July 2024) BDVAJ - Volume 7, Issue 1 (January 2024) BDVAJ - Volume 6, Issue 2 (December 2023) BDVAJ - Volume 6, Issue 1 (June 2023) BDVJ - Vol. 5 No. 2 (December 2022) BDVJ - Vol. 5 No. 1 (June 2022) BDVJ - Vol. 4 No. 2 (December 2021) BDVJ - Vol. 4 No. 1 (June 2021) BDVJ - Vol. 3 No. 2 (December 2020) BDVJ - Vol. 3 No. 1 (June 2020) BDVJ - Vol. 2 No. 2 (December 2019) BDVJ - Vol. 2 No. 1 (June 2019) BDVJ - Vol. 1 No. 2 (December 2018) BDVJ - Vol. 1 No. 1 (June 2018) More Issue